Serious complications and Zinbryta skin side effects have been linked to the medication ranging from patients complaining of adverse effects including encephalitis, liver failure, and Stevens Johnson Syndrome (SJS).

If you or someone you know have suffered from Zinbryta skin side effects, you may be eligible to join a lawsuit investigation or file a Zinbryta lawsuit.

On March 2, 2018, in a voluntary recall announced by the drug’s manufacturers, Biogen and Abbvie, Zinbryta was taken off the market. The manufacturers have chosen to do so given the nature and complexity of adverse events being reported with the drug.

Reports have included patients suffering from brain inflammation disorders such as meningoencephalitis and encephalitis. There have also been a range of other side effects including severe skin reactions and liver failure. In three of twelve encephalitis cases associated with Zinbryta reported worldwide, three have been fatal.

Overview: Zinbryta Skin Side Effects

Ever since the drug was introduced to the market in 2016, there have been a number of complications reportedly associated with the drug. These have included:

• Serious skin reactions, such as erythema multiforme, an early from of Stevens Johnson Syndrome (SJS). Without treatment, SJS may turn into an even more serious and complicated condition known as Toxic Epidermal Necrolysis (TEN). TEN is a skin disorder that mirrors severe skin burns and can be life-threatening.
• Liver injury and liver failure
• Encephalitis, among other severe immune reactions

Zinbryta (daclizumab) was approved by the U.S. Food and Drug Administration (FDA) on May 27, 2016 to help treat people diagnosed with multiple sclerosis (MS).

According to the U.S. National Library of Medicine (NCBI), multiple sclerosis is a disease that effects the body’s central nervous system. It is characterized by causing a loss of muscle coordination, numbness, and weakness. Other symptoms include problems with bladder control, vision, and speech.

MS is believed to be a kind of autoimmune disease in which the body’s immune system destroys myelin, a mixture of proteins creating a sheath around the body’s nerve fibers.

According to the NCBI, MS is an unpredictable disease and can range for being somewhat benign in from or absolutely devastating, as it cuts off communication between the brain and other parts of the body.

The FDA says it has become aware of the “complex safety profile of Zinbryta” since its approval. Furthermore, because of the drug’s complexity and nature of adverse events being associated with the medication, in the short time the drug has been on the market, a black box warning was added to the drug’s label. The warning label advised patients of risks including immune-mediated disorders and sever liver injuries. Zinbryta was also advised to only be prescribed to patients who had not responded well to two other MS medications.

Adverse effects being associated with Zinbryta have also included encephalitis, or the inflammation of brain tissue. Although encephalitis symptoms resemble someone suffereing from the flu, there are some common signs including fatigue, fever, muscle pain, coordination problems, irritability, stiff neck, light sensitivity, and headache.